CXCR4 and neoplasm: Another key axis is CXCL12/CXCR4 (Figure 2), whose activation results in enhanced ERK and PI3K/AKT signaling in tumor cells, directly linking to increased vascular invasion and poor clinical prognosis (39, 40).